29.06.2011 • NewsBelarussian Potash CoBPCfertilizer

Uralkali Still Sees Belaruskali As Takeover Target

Russian potash miner Uralkali sees rival producer Belaruskali as an attractive acquisition target, although a deal is unlikely soon, Uralkali CEO Vladislav Baumgertner said on Tuesday.

"Belaruskali is attractive as an M&A target ... It's unlikely this will happen in the short term," Baumgertner told a Renaissance Capital investor conference, adding that no talks are now happening.

Baumgarter also said the company would refinance around $1 billion in debt for daughter company Silvinit this autumn.

The companies, both owned by billionaire tycoon Suleiman Kerimov and associates, merged in a $23.9 billion deal earlier this year to form Russia's No. 1 potash producer.

Prospects for Uralkali to buy the Belarus potash group dimmed last week when Uralkali shareholder Alexander Nesis said a takeover was "complicated" and unlikely to take place.

Uralkali is considered to be the most likely buyer of Belaruskali if Belarus is forced to sell its most prized asset to ease its currency and economic crisis.

Baumgertner also said he expected potash prices to rise in the near future as the market is very strong and major miners are operating at full capacity.
"We cannot exclude that prices will reach $600 per ton by the end of the year," he said.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.